Vaccine therapy for prostate cancer

Urologic Clinics of North America

Volumn 26, Issue 2, 1999, Pages 365-374

  Tjoa, B A ^a   Elgamal, A A A ^a   Murphy, G P ^a  

^a NORTHWEST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CAPROMAB PENDETIDE IN 111; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; INTERLEUKIN 10; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT VACCINE;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOSTIMULATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINE PRODUCTION;

EID: 0032965309     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70076-8     Document Type: Article

References (55)

1. J. Austyn New insights into the mobilization and phagocytic activity of dendritic cells J Exp Med 183 1996 1287
2. A.B.H. Bakker G. Marland de Boer A.J. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro Cancer Res 55 1995 5330
3. H.D. Bear G.G. Hamad P.J. Kostuchenko Biologic therapy of melanoma with cytokines and lymphocytes Semin Surg Oncol 12 1996 436
4. A. Belledegrun W. Pierce R. Kaboo Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma J Urol 150 1993 1384
5. A. Bender M. Sapp G. Schuler Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood J Immunol Methods 196 1996 121
6. H. Berhard M.L. Disis S. Heimfeld Generation of immunostimulatory dendritic cells from human CD34+ hematopoetic progenitor cells of the bone marrow and peripheral blood Cancer Res 55 1995 1099
7. A.A. Elgamal M.J. Troychack G.P. Murphy Prostascint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients Prostate 37 1998 261
8. Elgamal AA, Murphy GP: Prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) current benefits and future value. Cancer Control, in press
9. V.H. Engelhard Structure of peptides associated with class I and class II MHC molecules Annu Rev Immunol 12 1994 181
10. W.D. Figg K. Ammerman N. Patronas Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer Cancer Invest 14 1996 513
11. P.S. Goedegebuure L.M. Douville H. Li Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal carcinoma: A pilot study J Clin Oncol 13 1995 1939
12. W. Herr J. Schneider A. Lohse Detection and quantification of blood derived CD8+ T lymphocytes secreting tumor necrosis factor a in response to HLA-A2.1-binding melanoma and viral peptide antigen J Immunol Methods 191 1996 131
13. J.S. Horoszewicz E. Kawinski G.P. Murphy Monoclonal antibodies to a new antigenic marker in epithelial prostate cells and serum of prostatic cancer patients Anticancer Res 7 1987 927
14. F.J. Hsu C. Benike F. Fagnoni Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells Nat Med 2 1996 52
15. R.S. Israeli C.T. Powell J.G. Corr Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen Cancer Res 54 1993 1807
16. M.K. Jenkins J.G. Johnson Molecules involved in T-cell costimulation Curr Opin Immunol 5 1993 361
17. G. Jones C. Mettlin G. Murphy Patterns of care for carcinoma of the prostate gland: Results of a national survey of 1984 and 1990 J Am Coll Surg 180 1995 545
18. M. Kawakami J. Nakayama Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization Cancer Res 15 1997 2321
19. Kim T. von Eschenbach A.C. M.D. Filaccio Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma Cancer Res 50 1990 5263
20. L. Klein Medical progress: Prostatic carcinoma N Engl J Med 300 1979 824
21. S.C. Knight J. Farrant A. Bryant Non-adherent, low-density cells from human peripheral blood contain dendritic cells and monocytes, both with veiled morphology Immunology 57 1985 595
22. S.C. Knight A.J. Stagg Antigen-presenting cell types Curr Opin Immunol 5 1993 374
23. J. Krikorian C. Portlock D. Cooney Spontaneous regression of non-Hodgkin's lymphoma: A report of nine cases Cancer 46 1980 2093
24. S. Landis T. Murray S. Bolden Cancer statistics, 1996 CA Cancer J Clin 48 1998 6
25. E. Maraskovsky H.J. McKenna K. Brasel In vivo administration of Flt3 ligand but not G-CSF nor GM-CSF results in the generation of large numbers of dendritic cells in mice Blood 86 1995 423
26. P. Marrack J. Kappler The T cell receptor Science 238 1987 1073
27. I. Melman S.J. Turley R.M. Steinman Antigen processing for amateurs and professionals Trends Cell Biol 8 1998 231
28. D. Mitropoulos S. Kooi J. Rodriguez-Villananueva Characterization of fresh (uncultured) tumor-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma Clin Exp Immunol 97 1994 321
29. B. Mukherji N.G. Chakraborty S. Yamasaki Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells Proc Natl Acad Sci USA 92 1995 8078
30. G. Murphy H. Ragde G. Kenny Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients Anticancer Res 15 1995 1473
31. Murphy G.P. Baren R.J. III S.J. Erickson Evaluation and comparison of two new prostate carcinoma markers Cancer 78 1996 809
32. G. Murphy B. Tjoa H. Ragde Phase I clinical trial: T cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen Prostate 29 1996 371
33. G.P. Murphy M.J. Troychak O.E. Cobb Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer Prostate 33 1997 141
34. F.O. Nestle S. Alijagic M. Gilliet Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nat Med 4 1998 328
35. D. Pardoll New strategies for active immunotherapy with genetically engineered tumor cells Curr Opin Immunol 4 1992 619
36. E. Ralfkiaer K. Hou-Jensen K. Gatter Immunohistological analysis of the lymphoid infiltrate in cutaneous malignant melanomas Virchows Arch 410 1987 355
37. T. Ranjeny L.S. Davis P.E. Lipsky Isolation and characterization of human peripheral blood dendritic cells J Immunol 150 1993 821
38. N. Romani S. Gruner D. Brang Proliferating dendritic cell progenitors in human blood J Exp Med 180 1994 83
39. S. Rosenberg M. Lotze J. Yang Experience with the use of high-dose interleukin-2 treatment of 652 cancer patients Ann Surg 210 1989 474
40. D. Ruiter A. Bhan T. Harrist Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma J Immunol 129 1982 2808
41. M. Salgaller P. Lodge J. McLean Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen Prostate 35 1998 144
42. Scheibenbogen C. Lee K.-H. S. Stevanovic Analysis of the T cell response to tumor and viral peptide antigens by an IFN-gamma ELISPOT assay Int J Cancer 71 1997 932
43. H. Sedlacek Vaccination for treatment of tumors: A critical comment Crit Rev Oncog 5 1994 555
44. S.F. Slovin K. Kelly H.I. Scher Immunological approaches for the treatment of prostate cancer Semin Urol Oncol 16 1998 53
45. R.M. Steinman The dendritic cell system and its role in immunogenicity Annu Rev Immunol 9 1991 271
46. B. Tjoa A. Boynton G. Kenny Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity Prostate 28 1996 65
47. B. Tjoa S. Erickson Barren R. III In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy Prostate 27 1995 63
48. B. Tjoa S. Erickson V. Bowes Follow-up evaluation of prostate cancer patients with autologous dendritic cells pulsed with PSMA peptides Prostate 32 1997 272
49. B. Tjoa S. Simmons V. Bowes Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides Prostate 36 1998 39
50. A.J. Troy D.N.J. Hart Dendritic cells and cancer: Progress toward a new cellular therapy J Hematother 6 1997 523
51. J.L. Urban H. Schreiber Tumor antigens Annu Rev Immunol 10 1992 617
52. van Elsas A. van der Burg S.H. van der Minne C. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self-antigen Eur J Immunol 26 1996 1683
53. M. Wang L. Valenzuela G. Murphy Purification of a human prostate-specific antigen Invest Urol 17 1979 159
54. A. Weiss D. Littman Signal transduction by lymphocyte antigen receptors Cell 76 1994 263
55. S. Zhang H.S. Zhang V.E. Rueter Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers Clin Cancer Res 4 1998 295